<DOC>
	<DOCNO>NCT01940276</DOCNO>
	<brief_summary>The primary goal prospectively estimate median radiographic PFS African American Caucasian men mCRPC abiraterone acetate prednisone .</brief_summary>
	<brief_title>Abiraterone Race Metastatic Castrate-resistant Prostate Cancer</brief_title>
	<detailed_description>This non-comparative pilot open-label , parallel arm , multicenter study abiraterone acetate African American Caucasian men mCRPC . Patients self-report race 50 patient enrol group . Patients treat open-label treatment evidence disease progression define Prostate Cancer Working Group Two ( PCWG2 ) definition two year point roll standard care time . The study agent abiraterone acetate administer patient dose 1000mg orally daily prednisone 5 mg BID 4-week cycle throughout treatment period .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Male , age ≥ 18 year Karnofsky performance status ≥ 70 Life expectancy ≥ 12 week Willing take abiraterone acetate empty stomach ; food consume least two hour least one hour dose abiraterone acetate take , able swallow tablet whole , without crushing/chewing tablet Patients partner childbearing potential must willing use method birth control adequate barrier protection determine acceptable principal investigator sponsor study 1 week last dose abiraterone acetate Adequate laboratory parameter Histologically confirm diagnosis adenocarcinoma prostate . Histologic variant prostate cancer , include neuroendocrine feature small cell carcinoma prostate exclude Radiographic evidence metastatic disease ; evaluable nontarget lesion and/or bone metastasis permit Ongoing ADT use LHRH agonist ( e.g . leuprolide , goserelin ) antagonist ( e.g . degarelix ) must continue therapy unless prior bilateral orchiectomy perform . Screening serum testosterone must &lt; 50 ng/dl PSA ≥ 2.0 ng/mL Evidence castration resistant disease ADT evidence one following : Absolute rise PSA 2.0 ng/mL great , minimum 2 consecutive rise PSA level interval ≥ 1 week PSA level , OR 2 consecutive PSA level 50 % great PSA nadir achieve ADT separate least 1 week apart , OR • CT MRI base evidence disease progression ( soft tissue , nodal visceral disease progression ) accord PCWG2 criterion RECIST 1.1 criterion , least 1 new bone scan lesion compare immediate prior radiologic study ) A minimum 2 week elapse antiandrogen therapy prior start study drug ( i.e . flutamide , nilutamide , bicalutamide ) A minimum 4 week elapse sipuleucelT prior start study drug A minimum 4 week major surgery prior start study drug Selfreported race either African American Caucasian Ability swallow , retain , absorb oral medication Prior treatment abiraterone acetate enzalutamide Active infection medical condition would make prednisone/prednisolone ( corticosteroid ) use contraindicate Any chronic medical condition require high dose corticosteroid 5mg prednisone/prednisolone bid Have know allergy , hypersensitivity , intolerance abiraterone acetate prednisone excipients Pathological find consistent small cell carcinoma prostate Symptomatic Liver visceral organ metastasis Have history gastrointestinal disorder ( medical disorder extensive surgery ) may interfere absorption study agent Known brain metastasis Prior cytotoxic chemotherapy biologic therapy treatment CRPC Previously treat ketoconazole prostate cancer great 7 day Prior systemic treatment azole drug ( e.g . fluconazole , itraconazole ) within 4 week Cycle 1 , Day 1 Uncontrolled hypertension ( systolic BP ≥ 160 mmHg diastolic BP ≥ 95 mmHg ) . Patients history hypertension allow provide blood pressure control antihypertensive treatment . Poorly control diabetes Active symptomatic viral hepatitis chronic liver disease History pituitary adrenal dysfunction Clinically significant heart disease evidence myocardial infarction , arterial thrombotic event past 6 month , severe unstable angina , New York Heart Association ( NYHA ) Class IIIV heart disease cardiac ejection fraction measurement &lt; 50 % baseline Atrial Fibrillation cardiac arrhythmia require therapy Other malignancy , except nonmelanoma skin cancer , ≥ 30 % probability recurrence within 24 month Administration investigational therapeutic within 30 day Cycle 1 , Day 1 Any condition , opinion investigator , would preclude participation trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>castrate resistant</keyword>
	<keyword>abiraterone acetate</keyword>
	<keyword>prednisone</keyword>
	<keyword>metastatic prostate cancer</keyword>
</DOC>